Reuters logo
BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​
November 29, 2017 / 6:09 AM / 15 days ago

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

Nov 29 (Reuters) - IPSEN SA:

* ‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​

* ‍STUDY WAS IN ADULT PATIENTS WITH LOWER LIMB SPASTICITY FOLLOWING A STROKE OR TRAUMATIC BRAIN INJURY​

* ‍MOST COMMON ADVERSE REACTIONS WERE: FALLS, MUSCULAR WEAKNESS, AND PAIN IN EXTREMITY​

* ‍WHILE MAJORITY OF PATIENTS WERE RE-TREATED AT WEEK 12, WERE TREATED AT WEEK 16 AND BEYOND​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below